{
    "clinical_study": {
        "@rank": "161443", 
        "arm_group": [
            {
                "arm_group_label": "IncobotulinumtoxinA (Xeomin) 25U per eye", 
                "arm_group_type": "Experimental", 
                "description": "Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
            }, 
            {
                "arm_group_label": "IncobotulinumtoxinA (Xeomin) 12.5U per eye", 
                "arm_group_type": "Experimental", 
                "description": "Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.\nOpen-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
            }
        ], 
        "brief_summary": {
            "textblock": "This phase 3 study will serve to collect efficacy and safety data of two different doses of\n      NT 201 in subjects suffering from Bilateral Blephorasm (BEB) who are BTX treatment-na\u00efve.\n\n      In this study, BTX treatment-na\u00efve subjects are defined as those who have not received BTX\n      treatment within the last 12 months for the treatment of BEB. This definition aims to avoid\n      bias by comparison of treatment effects in the subject's assessments. Furthermore, this\n      study will substantiate the existing efficacy and safety database for the indication BEB."
        }, 
        "brief_title": "Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Bilateral Blepharospasm (BEB)", 
        "condition_browse": {
            "mesh_term": "Blepharospasm"
        }, 
        "detailed_description": {
            "textblock": "Subjects to receive one injection with NT 201 or placebo at baseline of the\n      placebo-controlled first cycle. Thereafter, all subjects entering the Open-Label Extension\n      Period (OLEX) to receive a second injection of NT 201 (second injection cycle)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female out-patients age \u2265 18 and \u2264 80 years.\n\n          -  A clinical diagnosis of bilateral BEB characterized by spontaneous, spasmodic,\n             intermittent or persistent involuntary contractions of orbicular oculi muscles.\n\n          -  A need for injection of BTX defined as a Jankovic Rating Scale [JRS] severity\n             subscore \u2265 2.\n\n          -  Treatment-na\u00efve subject defined as at least 12 months without BTX of any serotype for\n             the treatment of BEB before administration of IP.\n\n        Exclusion Criteria:\n\n          -  Subject with any previous unsuccessful treatment with BTX of any serotype for the\n             treatment of BEB.\n\n          -  Atypical variant of BEB (e.g., apraxia of the eyelid opening) caused by inhibition of\n             levator palpebrae muscle.\n\n          -  Neuroleptic-induced blepharospasm.\n\n          -  Myotomy or denervation surgery in the affected muscles (e.g., peripheral denervation,\n             spinal cord stimulation) and surgery in the upper face.\n\n          -  Generalized disorders of muscles activity (e.g., myasthenia gravis in particular\n             ocularis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis) or any other\n             significant neuromuscular dysfunction which might interfere with the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896895", 
            "org_study_id": "MRZ60201_3074_1", 
            "secondary_id": "2012-004821-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "IncobotulinumtoxinA (Xeomin) 25U per eye", 
                "description": "IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.", 
                "intervention_name": "IncobulinumtoxinA (Xeomin), 25 Units", 
                "intervention_type": "Drug", 
                "other_name": [
                    "NT 201", 
                    "Xeomin", 
                    "Botulinum toxin type A (150 kiloDalton), free from complexing proteins"
                ]
            }, 
            {
                "arm_group_label": "IncobotulinumtoxinA (Xeomin) 12.5U per eye", 
                "description": "IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.", 
                "intervention_name": "IncobotulinumtoxinA (Xeomin), 12.5 Units", 
                "intervention_type": "Drug", 
                "other_name": [
                    "NT 201", 
                    "Xeomin", 
                    "Botulinum toxin type A (150 kiloDalton), free from complexing proteins"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IncobotulinumtoxinA (Xeomin) 25U per eye", 
                    "IncobotulinumtoxinA (Xeomin) 12.5U per eye", 
                    "Placebo"
                ], 
                "description": "IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).\nOpen-Label Extension: up to 35 Units per eye.", 
                "intervention_name": "IncobotulinumtoxinA (Xeomin), 35 Units", 
                "intervention_type": "Drug", 
                "other_name": [
                    "NT 201", 
                    "Xeomin", 
                    "Botulinum toxin type A (150 kiloDalton), free from complexing proteins"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11526"
                    }, 
                    "name": "Merz Investigational Site #030001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11521"
                    }, 
                    "name": "Merz Investigational Site #030002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ioannina", 
                        "country": "Greece", 
                        "zip": "45500"
                    }, 
                    "name": "Merz Investigational Site #030004"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece", 
                        "zip": "56429"
                    }, 
                    "name": "Merz Investigational Site #030003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kota Kinabalu", 
                        "country": "Malaysia", 
                        "state": "Sabah", 
                        "zip": "88586"
                    }, 
                    "name": "Merz Investigational Site #060004"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia", 
                        "zip": "56000"
                    }, 
                    "name": "Merz Investigational Site #060002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Selangor", 
                        "country": "Malaysia", 
                        "zip": "43000"
                    }, 
                    "name": "Merz Investigational Site #060003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anuradhapura", 
                        "country": "Sri Lanka", 
                        "zip": "50000"
                    }, 
                    "name": "Merz Investigational Site #094004"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colombo", 
                        "country": "Sri Lanka", 
                        "zip": "10350"
                    }, 
                    "name": "Merz Investigational Site #094005"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colombo", 
                        "country": "Sri Lanka", 
                        "zip": "10"
                    }, 
                    "name": "Merz Investigational Site #094003"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colombo", 
                        "country": "Sri Lanka", 
                        "zip": "07"
                    }, 
                    "name": "Merz Investigational Site #094001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nugegoda", 
                        "country": "Sri Lanka", 
                        "zip": "10250"
                    }, 
                    "name": "Merz Investigational Site #094002"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Greece", 
                "Malaysia", 
                "Sri Lanka"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Prospective, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of Two Different Doses of NT 201 in Botulinum Toxin Treatment-na\u00efve Subjects With Blepharospasm", 
        "overall_contact": {
            "email": "clinicaltrials@merz.de", 
            "last_name": "Public Disclosure Manager"
        }, 
        "overall_official": {
            "affiliation": "Merz Pharmaceuticals GmbH", 
            "last_name": "Merz Medical Expert", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Malaysia: Ministry of Health", 
                "India: Drugs Controller General of India", 
                "Sri Lanka: Ministry of Healthcare & Nutrition", 
                "Greece: National Organization of Medicines", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Jankovic Rating Scale (JRS) is used for classification of the patient's individual symptoms of blepharospasm and for determination of the therapeutic efficacy of study medication. The JRS-Severity sub-score is used, which ranges from 0 (=absence of severity) to 4 (=maximum severity).", 
            "measure": "Change from baseline in Jankovic rating scale (JRS) severity subscore determined at V4 (Week 6)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896895"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Blepharospasm Disability Index is a disease specific scale for subject functional self assessment of impairment of specific activities of daily living caused by blepharospasm. The BSDI consists of six items (driving a vehicle; reading; watching TV; shopping; getting about on foot (walking); doing everyday activities), each ranges from 0 (=no impairment) to 4 (=no longer possible due to illness). The BSDI will be assessed before rating the JRS for unbiased information by subject", 
                "measure": "Change from baseline in Blepharospasm Disability Index (BSDI) score at Visit 4 (week 6)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to week 6"
            }, 
            {
                "description": "The PEGR is a descriptive subjective 9-point response scale ranging from \"complete abolishment of signs and symptoms\" (value=+4) down to \"very marked worsening\" (value=-4).", 
                "measure": "Patient Evaluation of Global Response [PEGR] at final visit of Main Period (V5 -up to week 20)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 20"
            }
        ], 
        "source": "Merz Pharmaceuticals GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}